Jhanelle E. Gray
Institut Gustave Roussy
3 papers in the Anchorcite directory, published between 2017 and 2018, cited 17,109 times in total.
ORCID profileResearch topics
- Lung Cancer Diagnosis and Treatment · 3 papers
- Lung Cancer Treatments and Mutations · 3 papers
- Cancer Immunotherapy and Biomarkers · 2 papers
- HER2/EGFR in Cancer Research · 1 paper
Frequent co-authors
- Rina Hui · 2 papers
- Takayasu Kurata · 2 papers
- Ki Hyeong Lee · 2 papers
- Byoung Chul Cho · 2 papers
- David Planchard · 2 papers
- Leena Gandhi · 1 paper
- Delvys Rodríguez‐Abreu · 1 paper
- Shirish M. Gadgeel · 1 paper
Papers
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine · 2018 · 6,754 citations
BACKGROUND: First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the…
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine · 2017 · 5,640 citations
BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell…
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerNew England Journal of Medicine · 2017 · 4,715 citations
BACKGROUND: Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in…
Metadata from OpenAlex (CC0).